ライフサイエンスコーパス: allogeneic

1 stem cell transplantation (20 autologous, 26 allogeneic).

2 hematologic malignancies (HSCT N = 112 [70% allogeneic, 30% autologous]; conventionally treated N =

3 es the possibility of applying autologous or allogeneic ADSCs and ADSC-TM cells as a potential treatm

4 In this study of recipients of allogeneic (Allo) and autologous (Auto) hematopoietic ce

5 Blood transfusions are allogeneic, and when given posttransplant (PTBT) they ma

6 ward higher rejection/inflammation grades in allogeneic animals compared with syngeneic controls.

7 Allogeneic animals displayed significant aggravated macr

8 Genome-edited donor-derived allogeneic anti-CD19 chimeric antigen receptor (CAR) T c

9 Here, we employed allogeneic apoptotic splenocytes and discovered that the

10 indicate that the tolerogenic properties of allogeneic apoptotic splenocytes require MerTK transmiss

11 splenocytes from either syngeneic C57BL/6 or allogeneic BALB/c donors.

12 severe haemoglobinopathies can be cured with allogeneic blood or bone marrow transplantation, availab

13 Allogeneic blood or marrow transplantation (alloBMT) is

14 quality of life as well as increased risk of allogeneic blood transfusions.

15 No allogeneic blood was transfused.

16 males; 68.6% non-Hispanic whites; and 46.6% allogeneic BMT recipients).

17 in significantly lower incidence of GVHD in allogeneic BMT recipients.

18 eased risk of subsequent breast cancer among allogeneic BMT survivors (hazard ratio [HR], 3.7 [95% CI

19 d higher risk of subsequent breast cancer in allogeneic BMT survivors and a 4.6-fold higher risk in a

20 on (CR), 19 patients (10.3%) proceeded to an allogeneic bone marrow transplant, and the overall respo

21 principal determinant of lethality following allogeneic bone marrow transplantation (BMT).

22 pment of GVHD in the gut in murine models of allogeneic bone marrow transplantation (BMT).

23 ls mediating graft-versus-host disease after allogeneic bone marrow transplantation in mice.

24 Hematopoietic chimerism after allogeneic bone marrow transplantation may establish a s

25 ycosylation in a dose-dependent manner after allogeneic bone marrow transplantation, both in donor-de

26 Allogeneic bone marrow-derived mesenchymal stem/stromal

27 hat transplantation of PVPON/TA-encapsulated allogeneic C57BL/6 islets into diabetic NOD mice will pr

28 tions of this study, data suggests GTR using allogeneic cancellous bone graft and absorbable collagen

29 Furcation defects treated with GTR using an allogeneic cancellous bone graft and covered by an absor

30 Nevertheless, the use of allogeneic CAR T cells from donors has many potential ad

31 However, allogeneic CAR T cells may cause life-threatening graft-

32 The development of next-generation allogeneic CAR T cells to address these issues is an act

33 es, mainly based on gene editing, to produce allogeneic CAR T cells with limited potential for graft-

34 an encouraging step forward for the field of allogeneic CAR T cells, and UCART19 offers the opportuni

35 These improved allogeneic CAR-T cell products will pave the way for fur

36 the different sources of T cells for optimal allogeneic CAR-T cell therapy and describe the different

37 ificantly prolonged the fully MHC mismatched allogeneic cardiac graft survival in a donor-specific fa

38 ate proliferation and cytokine production in allogeneic CD4(+) and CD8(+) T cells.

39 onger response against DERAA(+) vs. DERAA(-) allogeneic cell lines in vitro, in line with an immunoge

40 ly focus on mesenchymal stem cells (MSCs) as allogeneic cell sources, based on availability and innat

41 tentially represent a therapeutic advance in allogeneic cell therapy for cardiac repair.

42 To address allogeneic cell therapy limitations, this study develope

43 are emerging as the most promising means of allogeneic cell therapy.

44 e suppression regimen that can be applied to allogeneic cell transplantation.

45 etus and cancer cells to induce tolerance to allogeneic cell-based therapies by modifying cells to ex

46 RA had microchimerism (Mc; pregnancy-derived allogeneic cells) carrying DERAA (DERAA-Mc) vs. 6% of he

47 for persistent innate immune responses after allogeneic cells.

48 V-specific CD8(+) T cells cross-reacted with allogeneic class-I HLA molecules.

49 um tumor necrosis factor-alpha compared with allogeneic controls.

50 recipient survival, compared with untreated allogeneic controls.

51 Recent work provided clinical evidence that allogeneic, cord blood CAR-NK cells induce high rates of

52 re, using a well-established murine model of allogeneic corneal transplantation, we investigated the

53 was administered to mice thrice a day after allogeneic corneal transplantation.

54 n vitro, in line with an immunogenic role of allogeneic DERAA.

55 the precise delivery of either autologous or allogeneic dermal fibroblasts and epidermal keratinocyte

56 tion of recipient blood and bone marrow with allogeneic donor cells after sublethal irradiation by a

57 somatic cell function capable of supporting allogeneic donor stem cell engraftment and regeneration

58 In adult pigs and goats, SSCT with allogeneic donor stem cells led to sustained donor-deriv

59 -term specific immunosuppression against the allogeneic donor.METHODSIn this phase I trial, patients

60 Our findings support the application of allogeneic EVs for therapeutic use in clinical studies i

61 for the first time, the feasibility of using allogeneic, genome-edited CAR T cells to treat patients

62 blockade successfully prevented rejection of allogeneic glial-restricted progenitors from immunocompe

63 tus, possessing paternal antigens, is a semi-allogeneic graft that can survive without immunosuppress

64 s of rejection reactions to ABO-incompatible allogeneic grafts and xenogeneic grafts from other speci

65 t the same time points as rejection of fully allogeneic grafts.

66 e beta thalassemia (Hb Sbeta), and underwent allogeneic haematopoietic cell transplantation between J

67 Allogeneic haematopoietic stem cell transplantation (all

68 port clinical and imaging outcomes following allogeneic haematopoietic stem cell transplantation (HSC

69 has previously been observed only following allogeneic haematopoietic stem cell transplantation(2,3)

70 Allogeneic haemopoietic cell transplantation substantial

71 Studies with autologous and allogeneic haemopoietic cell transplantation suggest tha

72 r improvement of preparative regimens before allogeneic haemopoietic stem cell transplantation (HSCT)

73 cells, tumour-infiltrating lymphocytes, and allogeneic haemopoietic stem-cell transplantation for ca

74 aemia after standard therapy with or without allogeneic haemopoietic stem-cell transplantation were r

75 Among 4905 1-year survivors of allogeneic HCT for hematologic malignancies (N = 4500) o

76 rophylaxis reduced HHV-6B reactivation after allogeneic HCT in a post hoc analysis of a randomized co

77 We reviewed records of adult SOT or allogeneic HCT recipients from 1 January 2013 to 31 Dece

78 We reviewed records of adult SOT or allogeneic HCT recipients from 1/1/2013-12/31/2017 to ch

79 antibody titers and seroprotection rates of allogeneic HCT recipients years after different schedule

80 In a longitudinal surveillance study among allogeneic HCT recipients, pre-HCT and weekly post-HCT n

81 ofovir for cytomegalovirus prophylaxis after allogeneic HCT to study the effect of brincidofovir on H

82 e basis of our prior data, mice that undergo allogeneic HCT with Tbet-knockout donors (AlloTbet) have

83 ariable revealed treatment with midostaurin, allogeneic HCT, ELN favorable-risk group, and lower WBC

84 In children and young adults undergoing allogeneic HCT, we quantified BKPyV viruria and viremia

85 and many will be referred for autologous or allogeneic HCT, which carries an extremely high risk of

86 ts had hematologic malignancies treatable by allogeneic HCT.

87 enefit from consolidation strategies such as allogeneic HCT.

88 ic T cells to predict CMV outcomes following allogeneic HCT.

89 to prevent or treat this complication after allogeneic HCT.

90 cells could be observed, and the addition of allogeneic healthy OCs increased the patients' NK functi

91 mportant cause of morbidity and mortality in allogeneic hematopoietic cell transplant (allo-HCT) reci

92 represent a significant complication facing allogeneic hematopoietic cell transplant (allo-HCT) reci

93 hematopoietic cell transplant (autoHCT) and allogeneic hematopoietic cell transplant (alloHCT).

94 ternational guidelines recommend vaccinating allogeneic hematopoietic cell transplant (HCT) recipient

95 herpesviral infection within 100 days after allogeneic hematopoietic cell transplant increases risk

96 t-versus-host disease (GVHD) occurring after allogeneic hematopoietic cell transplant is an allo-reac

97 liant on cytotoxic chemotherapy regimens and allogeneic hematopoietic cell transplant to achieve the

98 fecal and blood specimens from recipients of allogeneic hematopoietic cell transplant.

99 cant causes of morbidity and mortality after allogeneic hematopoietic cell transplant.

100 Although allogeneic hematopoietic cell transplantation (allo-HCT)

101 Allogeneic hematopoietic cell transplantation (allo-HCT)

102 In patients who received allogeneic hematopoietic cell transplantation (allo-HCT)

103 rtant cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (allo-HCT)

104 HD) is a life-threatening complication after allogeneic hematopoietic cell transplantation (allo-HCT)

105 taurin to intensive chemotherapy followed by allogeneic hematopoietic cell transplantation (alloHCT)

106 Allogeneic hematopoietic cell transplantation (alloHCT)

107 lly augment graft-vs-tumor effects following allogeneic hematopoietic cell transplantation (alloHCT),

108 ission remain at risk for relapse even after allogeneic hematopoietic cell transplantation (alloHCT).

109 s with primary immunodeficiencies undergoing allogeneic hematopoietic cell transplantation (HCT) for

110 A multivariate Cox model for OS using allogeneic hematopoietic cell transplantation (HCT) in f

111 omarkers of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT) in t

112 t week 24 versus placebo in CMV-seropositive allogeneic hematopoietic cell transplantation (HCT) reci

113 ) bloodstream infection (BSI) on outcomes of allogeneic hematopoietic cell transplantation (HCT) util

114 st disease (GvHD) is a major complication of allogeneic hematopoietic cell transplantation (HCT), med

115 In patients who undergo allogeneic hematopoietic cell transplantation (HCT), pos

116 rus 6B (HHV-6B) frequently reactivates after allogeneic hematopoietic cell transplantation (HCT).

117 Allogeneic hematopoietic cell transplantation at the tim

118 The success of allogeneic hematopoietic cell transplantation depends he

119 inal disease is a major cause of death after allogeneic hematopoietic cell transplantation for acute

120 e to predict event-free survival (EFS) after allogeneic hematopoietic cell transplantation for sickle

121 cute graft-versus-host disease (aGVHD) after allogeneic hematopoietic cell transplantation have poor

122 Allogeneic hematopoietic cell transplantation is indicat

123 BALF is associated with higher mortality in allogeneic hematopoietic cell transplantation recipients

124 st disease (GVHD) is a major complication of allogeneic hematopoietic cell transplantation that resem

125 radiation-induced hematopoietic syndrome is allogeneic hematopoietic cell transplantation, a therapy

126 gut GVHD and improved survival in a model of allogeneic hematopoietic cell transplantation, providing

127 tment groups, with and without censoring for allogeneic hematopoietic cell transplantation.

128 e (GVHD) is the most serious complication of allogeneic hematopoietic cell transplantation.

129 ced by providers who care for patients after allogeneic hematopoietic cell transplantation.

130 (GVHD) is a life-threatening complication of allogeneic hematopoietic cell transplantation.

131 KIRs) could reduce the risk of relapse after allogeneic hematopoietic cell transplantation.

132 IA) is a life-threatening complication among allogeneic hematopoietic stem cell transplant (alloSCT)

133 Allogeneic hematopoietic stem cell transplant (HSCT) can

134 reatable, and it recurs despite resection or allogeneic hematopoietic stem cell transplant.

135 Allogeneic hematopoietic stem cell transplantation (allo

136 environments, ie, in long-term survivors of allogeneic hematopoietic stem cell transplantation (allo

137 gastrointestinal microbiota and outcomes in allogeneic hematopoietic stem cell transplantation (allo

138 k and refractory hematological malignancies, allogeneic hematopoietic stem cell transplantation (allo

139 ains a major obstacle for the wider usage of allogeneic hematopoietic stem cell transplantation (allo

140 agents, the success and wider utilization of allogeneic hematopoietic stem cell transplantation (allo

141 Allogeneic hematopoietic stem cell transplantation (allo

142 Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT)

143 Total body irradiation (TBI) before allogeneic hematopoietic stem cell transplantation (HSCT

144 tic leukemia (B-ALL) patients relapsed after allogeneic hematopoietic stem cell transplantation (HSCT

145 th or without site-directed radiotherapy and allogeneic hematopoietic stem cell transplantation (HSCT

146 Allogeneic hematopoietic stem cell transplantation (HSCT

147 For many inborn errors of metabolism (IEM), allogeneic hematopoietic stem cell transplantation (HSCT

148 or or HLA-matched family donor is available, allogeneic hematopoietic stem cell transplantation (HSCT

149 ome (VOD/SOS) is a serious complication post allogeneic hematopoietic stem cell transplantation (HSCT

150 gical malignancies who underwent their first allogeneic hematopoietic stem cell transplantation (HSCT

151 pediatric recipients of either autologous or allogeneic hematopoietic stem cell transplantation (HSCT

152 tissues, the potential therapeutic effect of allogeneic hematopoietic stem cell transplantation (HSCT

153 Two-hundred fifty patients (12%) underwent allogeneic hematopoietic stem cell transplantation and 6

154 e with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation and w

155 hieved HIV-1 remission/functional cure after allogeneic hematopoietic stem cell transplantation from

156 Allogeneic hematopoietic stem cell transplantation is cu

157 Allogeneic hematopoietic stem cell transplantation is th

158 Allogeneic hematopoietic stem cell transplantation is th

159 ll transplantation, we evaluated 1,974 adult allogeneic hematopoietic stem cell transplantation patie

160 30 mortality, whereas underlying malignancy, allogeneic hematopoietic stem cell transplantation, and

161 mmunodeficiencies are generally treated with allogeneic hematopoietic stem cell transplantation, but

162 reatening infectious complications following allogeneic hematopoietic stem cell transplantation, desp

163 risk factors for skin cancer associated with allogeneic hematopoietic stem cell transplantation, we e

164 f infectious mortality in children following allogeneic hematopoietic stem cell transplantation, with

165 riants in genes that could be corrected with allogeneic hematopoietic stem cell transplantation.

166 m the extensive body of work in the field of allogeneic hematopoietic stem cell transplantation.

167 nts that could be potentially corrected with allogeneic hematopoietic stem cell transplantation.

168 disease (GVHD) remains a major limitation of allogeneic hematopoietic stem cell transplantation.

169 ajor cause for morbidity and mortality after allogeneic hematopoietic stem cell transplantation.

170 or B cells of a patient with AML cured after allogeneic hematopoietic stem cell transplantation.

171 the lymphoma, including autologous and even allogeneic hematopoietic stem cell transplantation.

172 nditioning therapy followed by autologous or allogeneic hematopoietic stem cell transplantation.

173 (GVHD) is a life-threatening complication of allogeneic hematopoietic stem cell transplantation.

174 y autologous T-cell reconstitution following allogeneic hematopoietic stem cell transplantation.

175 tion in adult CMV-seropositive recipients of allogeneic hematopoietic stem cell transplantation.

176 Allogeneic hematopoietic stem-cell transplantation for X

177 long-term follow-up study until 1 year after allogeneic hematopoietic stem-cell transplantation or un

178 esulting in multifold greater engraftment of allogeneic hepatocytes and substantially increased liver

179 neic hepatocytes engrafted in liver, whereas allogeneic hepatocytes were rejected but engrafted after

180 Syngeneic and allogeneic heterotopic penile transplantations were perf

181 c CD8(+) T cells capable of reacting against allogeneic HLA molecules.

182 Allogeneic, HLA-mismatched off-the-shelf third-party don

183 EC) subset is difficult to isolate, means an allogeneic hOMC therapy would be an attractive "off-the-

184 s (HSCs) are an important source for HSCs in allogeneic HSC transplantation, but a limited number and

185 dex of 60% or higher, and were indicated for allogeneic HSCT but considered at an increased risk for

186 th fludarabine as a conditioning regimen for allogeneic HSCT for older or comorbid patients with acut

187 In summary, after >2 years of follow-up, allogeneic HSCT in ALSP led to interval resolution of di

188 Allogeneic HSCT may be beneficial in ALSP by providing a

189 acute myeloid leukemia, to those undergoing allogeneic HSCT pre-engraftment, and to those receiving

190 Allogeneic HSCT seems to be an effective option to cure

191 been cured, these data suggest that a single allogeneic HSCT with homozygous CCR5Delta32 donor cells

192 Five patients with PAMI syndrome underwent allogeneic HSCT with myeloablative (4) or reduced-intens

193 ced haematological malignancies treatable by allogeneic HSCT, had a Karnofsky score greater than or e

194 on chemotherapy for ALL, autologous HSCT and allogeneic HSCT.

195 > 4 years old with high-risk ALL undergoing allogeneic HSCT.

196 ibility of intracerebral implantation of the allogeneic human neural stem cell line CTX0E03 in the su

197 Altogether, our findings support that the allogeneic immune response during acute GvHD might be in

198 scape of tumor cells from the control of the allogeneic immune response.

199 These results add to evidence establishing allogeneic islet transplant as a safe and effective trea

200 Allogeneic islet transplant offers a minimally invasive

201 None of the recipient of an intra-BM allogeneic islet transplantation had a primary nonfuncti

202 Allogeneic islet transplantation is limited by adverse e

203 s with type 1 diabetes receiving an intra-BM allogeneic islet transplantation: a feasibility study in

204 Allogeneic kidney transplantation led to death in all un

205 ngeneic limbs recovered quickly; however, in allogeneic limbs, macroscopic skin alterations were sign

206 ron-gamma levels were upregulated in skin of allogeneic limbs.

207 andomized Assessment of Clinical Events With Allogeneic Mesenchymal Precursor Cells in Advanced Heart

208 Allogeneic mesenchymal stem cells (MSCs) exhibit immunor

209 ngle infusion of up to 3 million cells/kg of allogeneic mesenchymal stem/stromal cells did not exacer

210 the first-in-human clinical trial evaluating allogeneic mesenchymal stem/stromal cells in septic shoc

211 Alternative approaches aim to infuse allogeneic mesenchymal stromal cells (MSCs) to provide a

212 lls had reduced reactivity to both self- and allogeneic MHC II.

213 To test this possibility, we utilized a full allogeneic mismatch murine transplant model and T follic

214 Furthermore, we observed that the allogeneic mixed lymphocytes reaction was suppressed in

215 human multiple myeloma xenografts and mouse allogeneic models to identify potential clinical transla

216 t- and long-term effects of cibinetide in an allogeneic mouse PITx model.

217 Intramyocardial injections of 150 million allogeneic MPCs or cryoprotective medium as a sham treat

218 Thus, allogeneic MSCs might suppress inflammation in lupus thr

219 Here we used an allogeneic murine islet transplantation tolerance model

220 en women developed subsequent breast cancer (allogeneic: n = 19; autologous: n = 18).

221 A total of 1,464 female BMT survivors (allogeneic: n = 788; autologous: n = 676) participated,

222 patients.METHODSWe developed a third-party, allogeneic, off-the-shelf bank of 330 GMP-grade EBV-CTL

223 on approaches combined with consolidation by allogeneic or autologous hematopoietic stem cell transpl

224 Syngeneic and allogeneic orthotopic hindlimb transplantations were per

225 e PEG-based hydrogel as an immunoisolator of allogeneic ovarian tissue to restore endocrine function

226 HAPa is a cancer vaccine consisting of allogeneic pancreatic cancer cells engineered to express

227 situ hybridization confirmed the presence of allogeneic parathyroid tissue in the patient's thymus tr

228 improved glycemic control immediately after allogeneic PITx and significantly delayed the onset of a

229 improved long-term graft survival following allogeneic PITx.

230 ficantly improve long-term graft survival in allogeneic PITx.

231 ves the overwhelming majority of third-party allogeneic pRBCs, but residual pRBCs within the organ ma

232 ade immune rejection in fully MHC-mismatched allogeneic recipients and survive long-term without the

233 DMOG treatment of allogeneic recipients improved survival by day +50, whic

234 ained graft survival and function in >90% of allogeneic recipients over a 100-d observation period.

235 DMOG treatment of allogeneic recipients resulted in increased hypoxia-indu

236 dified mPBMCs were transplanted into ablated allogeneic recipients, all recipients expired by day 40

237 ailed to prime CD4(+) T cells in response to allogeneic red-blood-cell transfusion.

238 une homeostasis with the ability to modulate allogeneic response and control transplant rejection.

239 esponses at multiple levels in this model of allogeneic RTx.

240 was injected on days 3, 17, 31, and 45 after allogeneic RTx.

241 itive relapse (high risk) were scheduled for allogeneic SCT after reinduction chemotherapy.

242 Allogeneic SCT offers a chance for cure in patients with

243 roof of principle, we tested our model in an allogeneic setting.

244 ression of CD28 accelerated the rejection of allogeneic skin grafts in young RAG2(-/-) recipient mice

245 skin followed by adoptive transfer of human allogeneic splenocytes.

246 With prepubertal mice, allogeneic SSCT resulted in attainment of natural fertil

247 rapy limitations, this study developed a new allogeneic stem cell sheet using human umbilical cord me

248 ansplant (AuSCT) and poor-risk patients (PR) allogeneic stem cell transplant (AlloSCT).

249 Allogeneic stem cell transplant, the only treatment moda

250 Allogeneic stem cell transplantation (alloSCT) of homozy

251 ith acute myeloid leukemia (AML) who undergo allogeneic stem cell transplantation (alloSCT), and carr

252 microbiome diversity plays a key role during allogeneic stem cell transplantation (ASCT), and loss of

253 was performed at a median of 8.6 years after allogeneic stem cell transplantation (range, 2-23 y) wit

254 is feasible as a conditioning regimen before allogeneic stem cell transplantation in diffuse large B-

255 Allogeneic stem cell transplantation is a cornerstone of

256 The success of allogeneic stem cell transplantation underscores the imm

257 ng for RUNX1 mutations in instances in which allogeneic stem cell transplantation using a related don

258 ble who survived at least 6 months following allogeneic stem cell transplantation without steroid-ref

259 the moderate graft-versus-myeloma effect of allogeneic stem cell transplantation.

260 in, checkpoint inhibitors, and autologous or allogeneic stem cell transplantation.

261 mary and post-ET/PV myelofibrosis undergoing allogeneic stem cell transplantation.

262 stigated 50 donor-recipient pairs undergoing allogeneic stem cell transplantation.

263 ng clinical decisions and overall success of allogeneic stem cell transplantations.

264 rently precludes the clinical utilization of allogeneic stem cells.

265 of 14 responders proceeding to a subsequent allogeneic stem-cell transplant.

266 lvage options for patients who relapse after allogeneic stem-cell transplantation (allo-SCT) for acut

267 e end of induction were allocated to undergo allogeneic stem-cell transplantation and those with low

268 mens have extended the curative potential of allogeneic stem-cell transplantation to older adults wit

269 plantation, or were otherwise ineligible for allogeneic stem-cell transplantation were enrolled.

270 ticipant 36 in the IciStem cohort) underwent allogeneic stem-cell transplantation with cells that did

271 row relapse, chemorefractory, relapsed after allogeneic stem-cell transplantation, or were otherwise

272 ontributing to mortality and morbidity after allogeneic stem-cell transplantation.

273 d glucocorticoid-refractory acute GVHD after allogeneic stem-cell transplantation.

274 disease (GVHD) remains a major limitation of allogeneic stem-cell transplantation; not all patients h

275 try, three (18%) patients had relapsed after allogeneic stem-cell transplants, 13 (76%) had previousl

276 erstanding of the immune response to chronic allogeneic stimulation.

277 Aggregate-treated moDCs enhanced allogeneic T cell proliferation and IL-5, IL-9, and IL-1

278 mine 2,3-dioxygenase induction and influence allogeneic T cell reactivity.

279 Although glycolysis is a main driver of allogeneic T cell-driven GVHD, oxidative phosphorylation

280 ated greater proliferation and activation of allogeneic T cells and secreted higher levels of inflamm

281 We further show that cocultured allogeneic T cells kill Atg16L1-mutant intestinal organo

282 Efforts to develop potent allogeneic T cells that are not rejected by the recipien

283 host T and NK cells, preventing rejection of allogeneic T cells.

284 uals harboring a common ATG16L1 variant from allogeneic T-cell attack.

285 I(2)=44.34%] of 901 patients), compared with allogeneic T-cell origin (29 [55%, 30.6-79.0, I(2)=62.64

286 ion of rejection-resistant, 'off-the-shelf', allogeneic T-cell products to produce long-term therapeu

287 tic cell maturation and subsequently reduced allogeneic T-cell response.

288 ned tumor eradication in two mouse models of allogeneic T-cell therapy of hematopoietic and solid can

289 entional CAR-T cells, and their potential in allogeneic therapies.

290 on of trillions of cells to support emerging allogeneic therapies.

291 Cotransplantation of allogeneic thymus and parental parathyroid tissue has be

292 mplete DiGeorge syndrome can be corrected by allogeneic thymus transplantation.

293 tion in complications were substantial after allogeneic transplant.

294 isease and hematologists who are considering allogeneic transplantation as a curative treatment relat

295 nd progenitor cells can be an alternative to allogeneic transplantation in the treatment of primary i

296 continuous-infusion chemotherapy followed by allogeneic transplantation was 67 +/- 12% compared with

297 relevant to cancer patients with preexisting allogeneic transplants or autoimmune disease who are und

298 Six syngeneic and 25 allogeneic transplants were performed.

299 otoxic T lymphocytes and function to destroy allogeneic transplants.

300 gen-specific manner a majority of HLA-A*0101 allogeneic tumor cell lines derived not only from PDAC,